Cardiovascular risk: Prevention and treatment of the metabolic syndrome

Diabetes Research and Clinical Practice

Volumn 68, Issue SUPPL. 2, 2005, Pages

  Tuomilehto, Jaakko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Lipid lowering; Metabolic syndrome; Rosuvastatin; Statin; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERAL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; VITAMIN;

ABDOMEN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; EXERCISE; HEALTH BEHAVIOR; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID DIET; METABOLIC SYNDROME X; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; RISK REDUCTION; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 20444372959     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.018     Document Type: Conference Paper

References (30)

1. World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus, Department of Noncommunicable Disease Surveillance, Geneva: World Health Organization, 1999.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.
3. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R.P. Tracy, and S.M. Haffner Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS) Circulation 102 2000 42 47
4. E.S. Ford The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey Atherosclerosis 168 2003 351 358
5. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787
6. H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, and J. Tuomilehto The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
7. G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnson, K. Pyorala DECODE Study Group Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women Arch. Intern. Med. 164 2004 1066 1076
8. P.W. Wilson, W.B. Kannel, H. Silbershatz, and R.B. D'Agostino Clustering of metabolic factors and coronary heart disease Arch. Intern. Med. 159 1999 1104 1109
9. S.M. Grundy Hypertriglyceridemia, insulin resistance, and the metabolic syndrome Am. J. Cardiol. 83 1999 25F 29F
10. C.M. Ballantyne, E.A. Stein, R. Paoletti, H. Southworth, and J.W. Blasetto Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome Am. J. Cardiol. 91 2003 25C 28C
11. M.C. Pouliot, J.P. Despres, A. Nadeau, S. Moorjani, D. Prud'Homme, and P.J. Lupien Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels Diabetes 41 1992 826 834
12. D.J. Nieves, M. Cnop, B. Retzlaff, C.E. Walden, J.D. Brunzell, and R.H. Knopp The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat Diabetes 52 2003 172 179
13. A. Festa, R. D'Agostino Jr., K. Williams, A.J. Karter, E.J. Mayer-Davis, and R.P. Tracy The relation of body fat mass and distribution to markers of chronic inflammation Int. J. Obes. Relat. Metab. Disord. 25 2001 1407 1415
14. I. Lemieux, A. Pascot, C. Couillard, B. Lamarche, A. Tchernof, and N. Almeras Hypertriglyceridemic waist: a marker of the atherogenic metabolic lipid triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102 2000 179 184
15. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, and J. Dallongeville European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice Eur. Heart J. 24 2003 1601 1610
16. J. Tuomilehto, J. Lindström, J.G. Eriksson, T.T. Valle, H. Hämäläinen, P. Ilanne-Parikka Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N. Engl. J. Med. 344 2001 1343 1350
17. P. Ilanne-Parikka, J.G. Eriksson, J. Lindstrom, H. Hamalainen, S. Keinanen-Kiukaanniemi, M. Laakso Finnish Diabetes Prevention Study Group Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the diabetes prevention study cohort Diabetes Care 27 2004 2135 2140
18. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 2002 393 403
19. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N. Engl. J. Med. 348 2003 383 393
20. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
21. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
22. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone CARDS investigators, primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
23. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, and E. Miller Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial) Am. J. Cardiol. 92 2003 152 160
24. J.M. McKenney, P.H. Jones, M.A. Adamczyk, V.A. Cain, B.S. Bryzinski, J.W. Blasetto STELLAR Study Group Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial Curr. Med. Res. Opin. 19 2003 689 698
25. A. Franken, B. Wolffenbuttel, and J. Vincent Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes Atheroscler. Suppl. 5 2004 118
26. C. Berne, and A. Siewert-Delle Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects Atheroscler. Suppl. 5 2004 107
27. D.J. Betteridge, and M. Gibson Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study Atheroscler. Suppl. 5 2004 107
28. H. Schuster, P.J. Barter, S. Stender, R.C. Cheung, J. Bonnet, and J.M. Morrell Effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study, effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study Am. Heart J. 147 2004 705 712
29. S. Stender, H. Schuster, P. Barter, R. Caplan, A. Raza, D. Kallend, MERCURY I Study Group, Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial, Diabetes Obes. Metab. (2004) (Epub).
30. A.F.H. Stalenhoef, C.M. Ballantyne, J. Tuomilehto, J. Murin, S. Tonstad, H. Rose COMETS Study Group A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study Diabetologia 47 2004 409 410